Fuzeon Articles
Row over Roche ARV in South Korea
12 January 2009
Trimeris reveals strategic plan
17 December 2007
Aptivus gives durable response in HIV patients
5 November 2007
Biojector withdrawn from US FDA review
15 October 2007
Strong female-specific data for Aptivus
6 August 2007
Combined Isentress and Fuzeon cuts HIV levels in study
12 March 2007
Fuzeon plus Prezista approved for HIV in EU
26 February 2007
Correction: Tibotec's Prezista
26 February 2007
Roche welcomes advent of Fuzeon/darunavir combo
22 December 2006
Roche's Fuzeon effective against resistant HIV
16 October 2006
CORRECTION: IAS HIV treatment guidelines
4 September 2006
Tibotec's darunavir approved in USA
3 July 2006
Trimeris' Fuzeon sees strong sales in 2005
13 February 2006
Roche/Trimeris extend anti-HIV drug pipeline
30 January 2006
Samaritan's HIV candidate in race for approval
22 August 2005
Roche and Trimeris file sNDA for needle-free Fuzeon
25 July 2005
FDA grants traditional approval for Fuzeon
25 October 2004
Stock Commentary - Europe
23 February 2004
Roche's Fuzeon shows reduced toxicity
23 February 2004
New Chemical Entities in 2003
19 January 2004
Roche and Trimeris halt trials of HIV drug
5 January 2004
US Medicare bill and biotech reimbursement
15 December 2003
Roche's Fuzeon more cost-effective in HIV
3 November 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
Fuzeon gives superior response in HIV
28 July 2003
Pfizer, GSK cut drug prices for US ADAPs
21 July 2003
Fuzeon launched in UK by Roche
7 July 2003
Roche's Fuzeon cleared in Switzerland
2 June 2003
Roche's Fuzeon wins European approval
2 June 2003
Stock Commentary - Europe
2 June 2003
California deficit hits AIDS free-drug plan
12 May 2003
Stock Commentary - Europe
31 March 2003
Positive CPMP view on Roche's Fuzeon
31 March 2003
Chronimed to distribute Fuzeon in USA
31 March 2003
AIDS group warns over Roche
17 March 2003
Fuzeon price pushes margin for HIV drugs
3 March 2003
Roche unveils data on new PI, T-1249
24 February 2003
GSK licenses HIV drug from Japan's Ono
27 January 2003
Roche predicts T-20 shortage
12 August 2002
Progenics says PRO 542 promising in Phase II
15 July 2002
Roche's T-20 effective in 2nd pivotal trial
27 May 2002
Showing 1-61 of 61 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
